Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients

Giuseppe Fossati, Silvana Canevari, Marco A. Pierotti, Paolo Vezzoni, Giuseppe Della Porta, Maurizio Vaglini

Research output: Contribution to journalArticle

Abstract

Crude soluble extracts from breast cancer and malignant melanoma surgical specimens were obtained by the 3 m KCl method and assayed in cancer patients for a delayed cutaneous hypersensitivity reaction. The breast cancer extract was derived from a pool of 9 primary cancer specimens, whereas 8 melanoma extracts were prepared from single tumors; as controls, normal mammary and muscle tissues were employed. Positive response to the breast cancer extract was observed In 18 of 26 (69%) breast cancer patients and in 2 of 12 (17%) patients with other types of neoplasms. Reactivity to the Individual melanoma extracts was varied: Positive reactions were observed in no patients with 1 extract, In 20-33% of the patients with 3 extracts, and In 75-93% with 4 extracts. By pooling the results obtained with the 8 melanoma extracts, we observed reactivity in 22 of 39 (56%) melanoma patients and in 12 of 23 (52%) patients with other tumors. Of 26 breast cancer patients, 5 (19%) reacted to normal mammary extract, and 5 of 28 (18%) melanoma patients reacted to muscle extracts; 20% and 25% of the patients with other types of tumors reacted to these extracts, respectively. The overall incidence of positive reactions to control extracts was 18 of 85 tests (21%). Ten of the 26 patients with breast cancer and 7 of the 39 patients with melanoma received simultaneous Injections of extracts from breast cancer and melanoma. Most breast cancer patients reacted both to the breast cancer extract (70%) and to the melanoma extracts (90%), whereas all the melanoma patients reacted to the melanoma extracts and 2 (28%) reacted to the breast cancer extract. No correlation was found between positive response and clinical parameters, e.g., histologic diagnosis, stage of disease, age, sex, blood group, history of pregnancy, and time of surgery.

Original languageEnglish
Pages (from-to)1381-1385
Number of pages5
JournalJournal of the National Cancer Institute
Volume62
Issue number6
DOIs
Publication statusPublished - 1979

Fingerprint

Delayed Hypersensitivity
Melanoma
Breast Neoplasms
Skin
Neoplasms
Breast
Muscles
Reproductive History
Blood Group Antigens
Complex Mixtures

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients. / Fossati, Giuseppe; Canevari, Silvana; Pierotti, Marco A.; Vezzoni, Paolo; Della Porta, Giuseppe; Vaglini, Maurizio.

In: Journal of the National Cancer Institute, Vol. 62, No. 6, 1979, p. 1381-1385.

Research output: Contribution to journalArticle

Fossati, Giuseppe ; Canevari, Silvana ; Pierotti, Marco A. ; Vezzoni, Paolo ; Della Porta, Giuseppe ; Vaglini, Maurizio. / Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients. In: Journal of the National Cancer Institute. 1979 ; Vol. 62, No. 6. pp. 1381-1385.
@article{82795655f25641e0aa5de833c8c9b8f8,
title = "Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients",
abstract = "Crude soluble extracts from breast cancer and malignant melanoma surgical specimens were obtained by the 3 m KCl method and assayed in cancer patients for a delayed cutaneous hypersensitivity reaction. The breast cancer extract was derived from a pool of 9 primary cancer specimens, whereas 8 melanoma extracts were prepared from single tumors; as controls, normal mammary and muscle tissues were employed. Positive response to the breast cancer extract was observed In 18 of 26 (69{\%}) breast cancer patients and in 2 of 12 (17{\%}) patients with other types of neoplasms. Reactivity to the Individual melanoma extracts was varied: Positive reactions were observed in no patients with 1 extract, In 20-33{\%} of the patients with 3 extracts, and In 75-93{\%} with 4 extracts. By pooling the results obtained with the 8 melanoma extracts, we observed reactivity in 22 of 39 (56{\%}) melanoma patients and in 12 of 23 (52{\%}) patients with other tumors. Of 26 breast cancer patients, 5 (19{\%}) reacted to normal mammary extract, and 5 of 28 (18{\%}) melanoma patients reacted to muscle extracts; 20{\%} and 25{\%} of the patients with other types of tumors reacted to these extracts, respectively. The overall incidence of positive reactions to control extracts was 18 of 85 tests (21{\%}). Ten of the 26 patients with breast cancer and 7 of the 39 patients with melanoma received simultaneous Injections of extracts from breast cancer and melanoma. Most breast cancer patients reacted both to the breast cancer extract (70{\%}) and to the melanoma extracts (90{\%}), whereas all the melanoma patients reacted to the melanoma extracts and 2 (28{\%}) reacted to the breast cancer extract. No correlation was found between positive response and clinical parameters, e.g., histologic diagnosis, stage of disease, age, sex, blood group, history of pregnancy, and time of surgery.",
author = "Giuseppe Fossati and Silvana Canevari and Pierotti, {Marco A.} and Paolo Vezzoni and {Della Porta}, Giuseppe and Maurizio Vaglini",
year = "1979",
doi = "10.1093/jnci/62.6.1381",
language = "English",
volume = "62",
pages = "1381--1385",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients

AU - Fossati, Giuseppe

AU - Canevari, Silvana

AU - Pierotti, Marco A.

AU - Vezzoni, Paolo

AU - Della Porta, Giuseppe

AU - Vaglini, Maurizio

PY - 1979

Y1 - 1979

N2 - Crude soluble extracts from breast cancer and malignant melanoma surgical specimens were obtained by the 3 m KCl method and assayed in cancer patients for a delayed cutaneous hypersensitivity reaction. The breast cancer extract was derived from a pool of 9 primary cancer specimens, whereas 8 melanoma extracts were prepared from single tumors; as controls, normal mammary and muscle tissues were employed. Positive response to the breast cancer extract was observed In 18 of 26 (69%) breast cancer patients and in 2 of 12 (17%) patients with other types of neoplasms. Reactivity to the Individual melanoma extracts was varied: Positive reactions were observed in no patients with 1 extract, In 20-33% of the patients with 3 extracts, and In 75-93% with 4 extracts. By pooling the results obtained with the 8 melanoma extracts, we observed reactivity in 22 of 39 (56%) melanoma patients and in 12 of 23 (52%) patients with other tumors. Of 26 breast cancer patients, 5 (19%) reacted to normal mammary extract, and 5 of 28 (18%) melanoma patients reacted to muscle extracts; 20% and 25% of the patients with other types of tumors reacted to these extracts, respectively. The overall incidence of positive reactions to control extracts was 18 of 85 tests (21%). Ten of the 26 patients with breast cancer and 7 of the 39 patients with melanoma received simultaneous Injections of extracts from breast cancer and melanoma. Most breast cancer patients reacted both to the breast cancer extract (70%) and to the melanoma extracts (90%), whereas all the melanoma patients reacted to the melanoma extracts and 2 (28%) reacted to the breast cancer extract. No correlation was found between positive response and clinical parameters, e.g., histologic diagnosis, stage of disease, age, sex, blood group, history of pregnancy, and time of surgery.

AB - Crude soluble extracts from breast cancer and malignant melanoma surgical specimens were obtained by the 3 m KCl method and assayed in cancer patients for a delayed cutaneous hypersensitivity reaction. The breast cancer extract was derived from a pool of 9 primary cancer specimens, whereas 8 melanoma extracts were prepared from single tumors; as controls, normal mammary and muscle tissues were employed. Positive response to the breast cancer extract was observed In 18 of 26 (69%) breast cancer patients and in 2 of 12 (17%) patients with other types of neoplasms. Reactivity to the Individual melanoma extracts was varied: Positive reactions were observed in no patients with 1 extract, In 20-33% of the patients with 3 extracts, and In 75-93% with 4 extracts. By pooling the results obtained with the 8 melanoma extracts, we observed reactivity in 22 of 39 (56%) melanoma patients and in 12 of 23 (52%) patients with other tumors. Of 26 breast cancer patients, 5 (19%) reacted to normal mammary extract, and 5 of 28 (18%) melanoma patients reacted to muscle extracts; 20% and 25% of the patients with other types of tumors reacted to these extracts, respectively. The overall incidence of positive reactions to control extracts was 18 of 85 tests (21%). Ten of the 26 patients with breast cancer and 7 of the 39 patients with melanoma received simultaneous Injections of extracts from breast cancer and melanoma. Most breast cancer patients reacted both to the breast cancer extract (70%) and to the melanoma extracts (90%), whereas all the melanoma patients reacted to the melanoma extracts and 2 (28%) reacted to the breast cancer extract. No correlation was found between positive response and clinical parameters, e.g., histologic diagnosis, stage of disease, age, sex, blood group, history of pregnancy, and time of surgery.

UR - http://www.scopus.com/inward/record.url?scp=0018745852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018745852&partnerID=8YFLogxK

U2 - 10.1093/jnci/62.6.1381

DO - 10.1093/jnci/62.6.1381

M3 - Article

C2 - 286110

AN - SCOPUS:0018745852

VL - 62

SP - 1381

EP - 1385

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -